المؤلفون: Philip G. Humphreys (1357530), Stephen J. Atkinson (1297362), Paul Bamborough (1343466), Rino A. Bit (1357536), Chun-wa Chung (1343454), Peter D. Craggs (7180412), Leanne Cutler (1738141), Rob Davis (9204195), Alan Ferrie (11920186), GangLi Gong (11920189), Laurie J. Gordon (1343442), Matthew Gray (2402251), Lee A. Harrison (2160145), Thomas G. Hayhow (3624884), Andrea Haynes (1399255), Nick Henley (11920192), David J. Hirst (1399282), Ian D. Holyer (11920195), Matthew J. Lindon (8232792), Cerys Lovatt (11920198), David Lugo (2803279), Scott McCleary (8232795), Judit Molnar (1357521), Qendresa Osmani (11920201), Chris Patten (8232804), Alex Preston (9105252), Inmaculada Rioja (8539), Jonathan T. Seal (2119816), Nicholas Smithers (487233), Fenglai Sun (11920204), Dalin Tang (835554), Simon Taylor (441637), Natalie H. Theodoulou (1508650), Clare Thomas (7943747), Robert J. Watson (1343463), Christopher R. Wellaway (7148462), Linrong Zhu (11920207), Nicholas C. O. Tomkinson (7417448), Rab K. Prinjha (449759)

مصطلحات موضوعية: Biochemistry, Medicine, Molecular Biology, Pharmacology, Biotechnology, Sociology, Immunology, Hematology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, potency agnostic analysis, orally bioavailable tetrahydroquinoline, medicinal chemistry strategy, bet567 (< b, appropriate lipophilicity space, oncology clinical trials, bromodomain oral candidate, bet candidate inhibitor, bet candidate, ‑ bet567, work describes, ultimately delivered, small group, sar knowledge, n <, mouse models, lysine group, human disease, histone tails, higher probability

Relation: https://figshare.com/articles/journal_contribution/Design_Synthesis_and_Characterization_of_I_BET567_a_Pan-Bromodomain_and_Extra_Terminal_BET_Bromodomain_Oral_Candidate/18064456

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c01747.s001

المؤلفون: Philip G. Humphreys (1357530), Stephen J. Atkinson (1297362), Paul Bamborough (1343466), Rino A. Bit (1357536), Chun-wa Chung (1343454), Peter D. Craggs (7180412), Leanne Cutler (1738141), Rob Davis (9204195), Alan Ferrie (11920186), GangLi Gong (11920189), Laurie J. Gordon (1343442), Matthew Gray (2402251), Lee A. Harrison (2160145), Thomas G. Hayhow (3624884), Andrea Haynes (1399255), Nick Henley (11920192), David J. Hirst (1399282), Ian D. Holyer (11920195), Matthew J. Lindon (8232792), Cerys Lovatt (11920198), David Lugo (2803279), Scott McCleary (8232795), Judit Molnar (1357521), Qendresa Osmani (11920201), Chris Patten (8232804), Alex Preston (9105252), Inmaculada Rioja (8539), Jonathan T. Seal (2119816), Nicholas Smithers (487233), Fenglai Sun (11920204), Dalin Tang (835554), Simon Taylor (441637), Natalie H. Theodoulou (1508650), Clare Thomas (7943747), Robert J. Watson (1343463), Christopher R. Wellaway (7148462), Linrong Zhu (11920207), Nicholas C. O. Tomkinson (7417448), Rab K. Prinjha (449759)

مصطلحات موضوعية: Biochemistry, Medicine, Molecular Biology, Pharmacology, Biotechnology, Sociology, Immunology, Hematology, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, potency agnostic analysis, orally bioavailable tetrahydroquinoline, medicinal chemistry strategy, bet567 (< b, appropriate lipophilicity space, oncology clinical trials, bromodomain oral candidate, bet candidate inhibitor, bet candidate, ‑ bet567, work describes, ultimately delivered, small group, sar knowledge, n <, mouse models, lysine group, human disease, histone tails, higher probability

Relation: https://figshare.com/articles/dataset/Design_Synthesis_and_Characterization_of_I_BET567_a_Pan-Bromodomain_and_Extra_Terminal_BET_Bromodomain_Oral_Candidate/18064459

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c01747.s002